Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Cell Stem Cell ; 30(5): 507-508, 2023 05 04.
Artigo em Inglês | MEDLINE | ID: mdl-37146577

RESUMO

Respiration exerts a mechanical strain on the lungs, which has an unclear effect on epithelial cell fate. Now in Cell, Shiraishi et al.1 reveal the crucial role of mechanotransduction in maintaining lung epithelial cell fate, representing a significant milestone in understanding how mechanical factors regulate differentiation.


Assuntos
Pulmão , Mecanotransdução Celular , Mecanotransdução Celular/fisiologia , Pulmão/fisiologia , Diferenciação Celular/fisiologia , Respiração , Células Epiteliais
2.
Cell Host Microbe ; 31(7): 1154-1169.e10, 2023 07 12.
Artigo em Inglês | MEDLINE | ID: mdl-37339625

RESUMO

Targeted protein degradation (TPD), as exemplified by proteolysis-targeting chimera (PROTAC), is an emerging drug discovery platform. PROTAC molecules, which typically contain a target protein ligand linked to an E3 ligase ligand, recruit a target protein to the E3 ligase to induce its ubiquitination and degradation. Here, we applied PROTAC approaches to develop broad-spectrum antivirals targeting key host factors for many viruses and virus-specific antivirals targeting unique viral proteins. For host-directed antivirals, we identified a small-molecule degrader, FM-74-103, that elicits selective degradation of human GSPT1, a translation termination factor. FM-74-103-mediated GSPT1 degradation inhibits both RNA and DNA viruses. Among virus-specific antivirals, we developed viral RNA oligonucleotide-based bifunctional molecules (Destroyers). As a proof of principle, RNA mimics of viral promoter sequences were used as heterobifunctional molecules to recruit and target influenza viral polymerase for degradation. This work highlights the broad utility of TPD to rationally design and develop next-generation antivirals.


Assuntos
Antivirais , Vírus , Humanos , Antivirais/farmacologia , Proteólise , RNA Viral/metabolismo , Ligantes , Vírus/metabolismo , Ubiquitina-Proteína Ligases/metabolismo , Proteínas Virais/metabolismo , Proteínas de Transporte/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA